Role of coagulation inhibitors in inflammation

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 51-56

  Esmon, C T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Endothelium; Inflammation; Natural anticoagulants; Sepsis; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; CALCIUM ION; CELL ADHESION MOLECULE; ENDOTOXIN; ESCHERICHIA COLI ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PROSTACYCLIN; PROTEIN C; PROTEINASE; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CALCIUM TRANSPORT; CELL ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INHIBITION KINETICS; LEUKOCYTE ACTIVATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RISK BENEFIT ANALYSIS; SEPSIS;

EID: 0034912330     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616200     Document Type: Conference Paper

References (70)

1. Efficacy and safety of recombinant human activated protein C for severe sepsis
2. Report of the international meeting on Intensive Care Medicine, Rome, Italy, October 1-4, 2000
3. Early events in the formation of a venous thrombus following local trauma and stasis
4. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction
5. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
6. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy
7. Thrombin receptor function and cardiovascular disease
8. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils
9. New potential therapeutic modalities: Tissue factor pathway inhibitor
10. Therapeutic rationale for antithrombin III in sepsis
11. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C
12. EPCR plays an important role in protein C activation in vivo
13. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia
14. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
15. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin
16. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion
17. Antithrombin III (AT III) prevents LPS-induced vascular injury: Novel biological activity of AT III
18. Sulfated polysaccharide-directed recruitment of mammalian host proteins: A novel strategy in microbial pathogenesis
19. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
20. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
21. Regulation of coagulation by a multivalent Kunitz-type inhibitor
22. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
23. 2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active
24. Coagulation factors VIIa and Xa induce cell signaling leading to upregulation of the egr-1 gene
25. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain
26. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
27. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs
28. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
29. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane
30. Tissue factor pathway inhibitor (TFPI) reduces mortality from Escherichia coli septic shock
31. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
32. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
33. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
34. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
35. Use of endothelium cultured on microcarriers as a model for the microcirculation
36. The roles of protein C and thrombomodulin in the regulation of blood coagulation
37. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor
38. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
39. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation
40. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor
41. Targeted disruption of the endothelial protein C receptor (EPCR) causes early embryonic lethality in mice
42. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system
43. The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors
44. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function
45. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
46. Endogenous anticoagulation during extracorporeal perfusion: Generation of a heparin-like inhibitor
47. Extracorporeal perfusion without exogenous anticoagulation: Its protective role in endotoxin shock
48. Activation of protein C in vivo
49. A model for thrombin protection against endotoxin
50. Activated protein C prevents E. coli induced coagulopathy and shock in the primate
51. C4b-binding protein exacerbates the host response to Escherichia coli
52. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
53. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
54. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation
55. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
56. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes
57. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte dependent proliferative responses
58. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line
59. Endothelial cell protein C receptor (EPCR) constitutively translocates into the nucleus and also mediates activated protein C, but not protein C, nuclear translocation
60. Endothelial protein C receptor
61. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner
62. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
63. Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S
64. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
65. Protein C in the treatment of coagulopathy in meningococcal disease
66. Infectious pupura fulminans: Diagnosis and treatment
67. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
68. Treatment of purpura fulminans in meningococcemia with protein C concentrate
69. Molecular mechanisms of thrombosis in meningococcal septicaemia: The role of the protein C pathway in vivo
70. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis